Workshop To Address NGS Draft Guidances
Executive Summary
US FDA is holding a workshop at NIH headquarters on Sept. 23 to get public feedback on two important draft guidances that provide sponsors with more clarity on the agency's thinking on next-generation sequencing tests.
You may also be interested in...
US FDA Gives More Time For Public Response To NGS Microbial Identification Guidance
To give stakeholders more time to respond, FDA has extended its comment period on a draft guidance that addresses next-generation sequencing tests that are used to detect microbes and antimicrobial resistance.
FDA Maps Out Novel Path For NGS Market Access
FDA Commissioner Robert Califf says the agency has worked with NIH and other experts as part of President Obama's Precision Medicine Initiative to map out a new regulatory framework for next-generation sequencing. He said two new draft guidances are meant to help get such tests to market sooner without requiring developers to validate individual genetic variations.
Precision Medicine Plan 'Golden Opportunity' For Device, Diagnostic Firms
A new proposed framework to realize President Obama's Precision Medicine Initiative has significant potential for device and diagnostic companies, according to NIH Director Francis Collins. He says it will give them a "competitive opportunity" to develop cheaper whole genome sequencing tests and open the door to other exciting technologies.